公开(公告)号：US11135239B1

公开(公告)日：2021-10-05

申请号：US17199736

申请日：2021-03-12

Applicant: Novartis AG

Inventor： Christoph Bucher ,  Dietmar Flubacher ,  Jeremiah Douglas Foutch ,  Malay Ghosh ,  Johannes Franz Kluge ,  Zaixing Li ,  Cale Ry McAlister ,  Liladhar Murlidhar Waykole ,  Jens Sören Worthmann ,  Tingying Zhu

IPC: A61K31/724 ,  A61K31/381 ,  C07D339/04 ,  A61K47/38 ,  A61K47/02 ,  C07C309/72

Abstract: The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.

公开(公告)号：US20250002499A1

公开(公告)日：2025-01-02

申请号：US18422517

申请日：2024-01-25

Applicant: Novartis AG

Inventor： Sung David C. Kim ,  Zaixing Li ,  Chui Lu ,  Danuta Lubicka ,  James Neef ,  Hye-Yeon Park ,  Tejaskumar Pankajbhai Pathak ,  Amir Masoud Sadaghiani ,  Xilin Zhou

IPC: C07D491/048 ,  C07D221/04

Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.

公开(公告)号：US10919887B2

公开(公告)日：2021-02-16

申请号：US15762724

申请日：2016-09-20

Applicant: Novartis AG

Inventor： Eric Aubin ,  Anthony Casarez ,  Andreas Fisch ,  Zaixing Li ,  Mika Lindvall ,  Heinz Ernst Moser ,  Michael Mutz ,  Folkert Reck ,  Bernd Ulrich Riebesehl ,  Marc Schoenhentz ,  Vijay Sethuraman ,  Robert Lowell Simmons

IPC: C07D417/14 ,  A61P31/04

Abstract: The invention provides new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.

公开(公告)号：US20210283171A1

公开(公告)日：2021-09-16

申请号：US17199736

申请日：2021-03-12

Applicant: Novartis AG

Inventor： Christoph Bucher ,  Dietmar Flubacher ,  Jeremiah Douglas Foutch ,  Malay Ghosh ,  Johannes Franz Kluge ,  Zaixing Li ,  Cale Ry McAlister ,  Liladhar Murlidhar Waykole ,  Jens Sören Worthmann ,  Tingying Zhu

IPC: A61K31/724 ,  A61K31/381 ,  C07D339/04 ,  C07C309/72 ,  A61K47/38 ,  A61K47/02

Abstract: The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.

公开(公告)号：US11590158B2

公开(公告)日：2023-02-28

申请号：US17463391

申请日：2021-08-31

Applicant: Novartis AG

Inventor： Christoph Bucher ,  Dietmar Flubacher ,  Jeremiah Douglas Foutch ,  Malay Ghosh ,  Johannes Franz Kluge ,  Zaixing Li ,  Cale Ry McAlister ,  Liladhar Murlidhar Waykole ,  Jens Sören Worthmann ,  Tingying Zhu

IPC: A61K31/724 ,  C07C309/72 ,  A61K31/381 ,  A61K47/02 ,  A61K47/38 ,  C07D339/04

Abstract: The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.

公开(公告)号：US20210393671A1

公开(公告)日：2021-12-23

申请号：US17463391

申请日：2021-08-31

Applicant: Novartis AG

Inventor： Christoph Bucher ,  Dietmar Flubacher ,  Jeremiah Douglas Foutch ,  Malay Ghosh ,  Johannes Franz Kluge ,  Zaixing Li ,  Cale Ry McAlister ,  Liladhar Murlidhar Waykole ,  Jens Sören Worthmann ,  Tingying Zhu

IPC: A61K31/724 ,  A61K47/02 ,  A61K47/38 ,  C07D339/04 ,  A61K31/381 ,  C07C309/72

Abstract: The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.

公开(公告)号：US12187703B2

公开(公告)日：2025-01-07

申请号：US17610321

申请日：2020-05-12

Applicant: NOVARTIS AG

Inventor： Cornelius Stephen Harlacher ,  Zaixing Li ,  Liladhar Murlidhar Waykole

IPC: C07D401/12

Abstract: The present invention relates to crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinanmide and to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-trifluoromethyl)isonicotinamide, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of cancers.

公开(公告)号：US11919911B2

公开(公告)日：2024-03-05

申请号：US17346006

申请日：2021-06-11

Applicant: Novartis AG

Inventor： Sung David C. Kim ,  Zaixing Li ,  Chui Lu ,  Danuta Lubicka ,  James Neef ,  Hye-Yeon Park ,  Tejaskumar Pankajbhai Pathak ,  Amir Masoud Sadaghiani ,  Xilin Zhou

IPC: C07D491/048 ,  C07D221/04

CPC classification number: C07D491/048 ,  C07D221/04 ,  C07B2200/13

Abstract: The present disclosure provides for a compound according to formula (I)




or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.

公开(公告)号：US20210395261A1

公开(公告)日：2021-12-23

申请号：US17346006

申请日：2021-06-11

Applicant: Novartis AG

Inventor： Sung David C. Kim ,  Zaixing Li ,  Chui Lu ,  Danuta Lubicka ,  James Neef ,  Hye-Yeon Park ,  Tejaskumar Pankajbhai Pathak ,  Amir Masoud Sadaghiani ,  Xilin Zhou

IPC: C07D491/048 ,  C07D221/04

Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.